Who sells Acceleron Pharma (xlrn) stock?
XLRN stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Joseph S Zakrzewski, Kevin F Mclaughlin, Sujay Kango, and Thomas A Mccourt.
What is Acceleron Pharma?
Acceleron Pharma Inc. is a biopharmaceutical company. It is focused on discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on natural regulators of cellular growth and repair, mainly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Do analysts agree on Acceleron Pharma (ACP) stock's target price?
The company's average rating score is 2.29, and is based on 4 buy ratings, 10 hold ratings, and no sell ratings. According to analysts' consensus price target of $172.15, Acceleron Pharma has a forecasted downside of 3.7% from its current price of $178.75.
What's the return on equity for Acceleron Pharma?
Acceleron Pharma had a negative net margin of 226.01% and a negative trailing twelve-month return on equity of 32.11%. The business's revenue was up 51.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.66) EPS. View Acceleron Pharma's earnings history.
Should I buy or sell Acceleron Pharma stock right now?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 9 hold ratings and...
What is Acceleron Pharma's stock price forecast for 2022?
11 brokerages have issued 1-year target prices for Acceleron Pharma's stock. Their forecasts range from $160.00 to $183.00. On average, they predic...
How were Acceleron Pharma's earnings last quarter?
Acceleron Pharma Inc. (NASDAQ:XLRN) posted its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.16...
Who are Acceleron Pharma's key executives?
Acceleron Pharma's management team includes the following people: Habib J. Dable , President, Chief Executive Officer & Director ( LinkedIn Prof...
What is Habib Dable's approval rating as Acceleron Pharma's CEO?
11 employees have rated Acceleron Pharma CEO Habib Dable on Glassdoor.com . Habib Dable has an approval rating of 100% among Acceleron Pharma's em...
Who are some of Acceleron Pharma's key competitors?
Some companies that are related to Acceleron Pharma include BioNTech (BNTX) , Biogen (BIIB) , Seagen (SGEN) , argenx (ARGX) , Novozymes A/S (N...
What other stocks do shareholders of Acceleron Pharma own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squib...
What is Acceleron Pharma's stock symbol?
Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."
What is Acceleron Pharma's stock price today?
One share of XLRN stock can currently be purchased for approximately $178.75.
When will Acceleron Pharma release its earnings?
What is Acceleron Pharma's ticker symbol?
Acceleron Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Acceleron Pharma.
What percentage of Acceleron Pharma is held by institutions?
Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."
What is Acceleron Pharma?
90.35% of the stock of Acceleron Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
What is the P/E ratio of Acceleron Pharma?
is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.
Does Acceleron Pharma pay dividends?
The P/E ratio of Acceleron Pharma is -42.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.